ClinicalTrials.gg

Program

BLN-481

A development code.

Its studies are led by Beeline Medicines.

Furthest: phase 1, since Oct 8, 20261 company-led study, 1 open or runningNext primary completion: Nov 24, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beeline Medicines11 open or runningphase 1since Oct 8, 2026Oct 8, 2026Nov 24, 2027phase 1 · NCT07903064

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 8, 2026First study: phase 1 study in Healthy Volunteers (no Disease Condition Under Study)First studyNCT07903064 · 104 planned · Australia

Ahead

  1. Nov 24, 2027Primary completion: phase 1 study in Healthy Volunteers (no Disease Condition Under Study)NCT07903064

TargetBeta

IL18 →read by rule
“BLN-481 is a monoclonal allosteric blocking antibody targeting IL-18 receptor beta (IL-18Rβ).”study text, by rule · the study

Other programs on IL18

ProgramCompanyFurthest phaseStudies
aletekitugruleGlaxoSmithKlinephase 29
arumakimigNovartisphase 27
camoteskimabruleapollo-therapeutics-ltdphase 25
GHZ339Novartisphase 21
GSK4528287GlaxoSmithKlinephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07903064Healthy Volunteers (no Disease Condition Under Study) · Australia1RecruitingNov 24, 2027104

How it is read

Names in the registry

  • “BLN-481”, 1 entry

Codes read as this program: BLN481.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.